PT  - JOURNAL ARTICLE
AU  - Switzer, Benjamin
AU  - Haanen, John
AU  - Lorigan, Paul C
AU  - Puzanov, Igor
AU  - Turajlic, Samra
TI  - Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
AID  - 10.1136/jitc-2021-002835
DP  - 2021 Jul 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e002835
VI  - 9
IP  - 7
4099  - http://jitc.bmj.com/content/9/7/e002835.short
4100  - http://jitc.bmj.com/content/9/7/e002835.full
SO  - J Immunother Cancer2021 Jul 01; 9
AB  - The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.